RA Session II, Taysha

Taysha Gene Ther­a­pies looks to build on rapid IPO with $85M dev-man­u­fac­tur­ing plant in North Car­oli­na

Taysha Gene Ther­a­pies went pub­lic with a bang ear­li­er this year with a $157 mil­lion IPO just five months af­ter its Se­ries A fi­nanc­ing. Now, with the help of the city of Durham, North Car­oli­na, Taysha is plot­ting an ex­pan­sive de­vel­op­ment and man­u­fac­tur­ing fa­cil­i­ty to ramp up sup­plies for the clin­ic — and po­ten­tial­ly the com­mer­cial mar­ket.

The new 187,000-square-foot cGMP plant will cre­ate rough­ly 200 jobs for Taysha Gene Ther­a­pies, which formed in late 2019 with the sole fo­cus of de­vel­op­ing ther­a­peu­tics for mono­genic dis­eases us­ing an ade­no-as­so­ciate virus method­ol­o­gy. The an­nounce­ment con­tin­ues a rapid as­cent for Taysha, which launched Se­ries A fi­nanc­ing just in April, and a mere five months lat­er had its own Nas­daq tick­er, of­fer­ing a $157 mil­lion IPO and pric­ing shares at $20 apiece.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.